# BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

> **NCT00396370** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 69 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** BCG strain Connaught
- **BIOLOGICAL:** BCG strain Danish
- **BIOLOGICAL:** BCG strain Danish
- **OTHER:** Placebo
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00396370
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-02
- **Primary completion:** 2012-07-23
- **Final completion:** 2012-07-23
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396370, "BCG Vaccination Delivered Intradermally, Orally and by Combined Routes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00396370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*